Table 6.
Risk for squamous-cell carcinoma (SCC) associated with risk factors other than GVHD in multivariate analyses adjusted for duration of chronic GVHD therapy
| Risk factors | Case patients, no. | Control patients, no. | RR | 95% CI | P |
|---|---|---|---|---|---|
| Transplantation-related factors | |||||
| Any TBI in conditioning regimen | |||||
| No | 28 | 70 | 1.00 | Reference | - |
| Yes | 30 | 85 | 0.40 | 0.13-1.24 | .11 |
| High-dose TBI conditioning regimen, 13 Gy or higher | |||||
| No | 35 | 98 | 1.00 | Reference | - |
| Yes | 23 | 57 | 0.99 | 0.44-2.22 | .98 |
| Any limited field radiation (TLI, TAI) as part of the conditioning regimen | |||||
| No | 49 | 140 | 1.00 | Reference | - |
| Yes | 9 | 15 | 3.07 | 0.37-37.63 | .27 |
| T-cell depletion of donor bone marrow | |||||
| No | 52 | 146 | 1.00 | Reference | - |
| Yes | 6 | 9 | 1.76 | 0.52-5.95 | .36 |
| Use of ATG in conditioning regimen or as GVHD prophylaxis or therapy | |||||
| No | 50 | 135 | 1.00 | Reference | - |
| Yes | 8 | 20 | 1.02 | 0.39-2.65 | .97 |
| Donor-recipient relationship | |||||
| HLA identical sibling | 54 | 142 | 1.00 | Reference | - |
| HLA mismatched donor | 2 | 10 | 0.82 | 0.17-4.05 | .81 |
| Unrelated donor | 2 | 3 | 1.18 | 0.09-15.83 | .90 |
| Treatment of primary disease before transplantation | |||||
| Pretransplantation RT | |||||
| None, RT to distant site | 52 | 140 | 1.00 | Reference | - |
| Yes, RT within or near second cancer site | 5 | 12 | 6.98 | 0.38-128.7 | .19 |
| Unknown RT | 1 | 3 | - | - | - |
| Duration of pretransplantation chemotherapy, mo | |||||
| None | 12 | 31 | 1.00 | Reference | - |
| 1-11 | 29 | 83 | 0.49 | 0.13-1.86 | .30 |
| 12 or greater | 12 | 33 | 0.66 | 0.14-3.08 | .59 |
| Unknown chemotherapy or duration | 5 | 8 | - | - | - |
| Duration of pretransplantation alkylating agent therapy, mo | |||||
| None | 45 | 119 | 1.00 | Reference | - |
| 1-5 | 5 | 14 | 0.78 | 0.19-3.14 | .73 |
| 6 or greater | 6 | 17 | 1.28 | 0.37-4.43 | .70 |
| Unknown duration | 2 | 5 | - | - | - |
| Pretransplantation chemotherapy, including epipodophyllotoxins | |||||
| No | 51 | 141 | 1.00 | Reference | - |
| Yes | 5 | 11 | 1.10 | 0.31-3.94 | .88 |
| Unknown | 2 | 3 | - | - | - |
| Follow-up after transplantation | |||||
| Disease relapse or recurrence | |||||
| No | 57 | 138 | 1.00 | Reference | |
| Yes | 1 | 17 | 0.16 | 0.18-1.39 | .09 |
Analyses were based on 58 case patients and 155 control patients.
TBI indicates total body irradiation; TLI, total lymphoid irradiation; TAI, thoraco-abdominal irradiation; ATG, antithymocyte/antilymphocyte globulin or serum; RT, radiation therapy.